Acquisition by Aromando Andrew of 389000 shares of Ambrx Biopharma subject to Rule 16b-3
AMAMDelisted Stock | USD 15.73 0.71 4.73% |
About 55% of Ambrx Biopharma's investors are presently thinking to get in. The analysis of current outlook of investing in Ambrx Biopharma American suggests that some traders are interested regarding Ambrx Biopharma's prospects. Ambrx Biopharma's investing sentiment overview a quick insight into current market opportunities from investing in Ambrx Biopharma American. Many technical investors use Ambrx Biopharma American stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Ambrx |
Filed transaction by Ambrx Biopharma Inc officer. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at macroaxis.com
Ambrx Biopharma Fundamental Analysis
We analyze Ambrx Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ambrx Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ambrx Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Ambrx Biopharma is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Ambrx Biopharma American Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ambrx Biopharma stock to make a market-neutral strategy. Peer analysis of Ambrx Biopharma could also be used in its relative valuation, which is a method of valuing Ambrx Biopharma by comparing valuation metrics with similar companies.
Peers
Ambrx Biopharma Related Equities
IMMX | Immix Biopharma | 19.39 | ||||
XFOR | X4 Pharmaceuticals | 11.43 | ||||
ENVB | Enveric Biosciences | 3.13 | ||||
ABOS | Acumen Pharmaceuticals | 2.73 | ||||
INZY | Inozyme Pharma | 2.64 | ||||
DAWN | Day One | 1.33 | ||||
ZURA | Zura Bio | 0.33 | ||||
ELEV | Elevation Oncology | 1.59 | ||||
OCEA | Ocean Biomedical | 2.74 | ||||
HEPA | Hepion Pharmaceuticals | 4.48 | ||||
SONN | Sonnet Biotherapeutics | 5.05 | ||||
CNSP | Cns Pharmaceuticals | 7.69 |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Ambrx Stock
If you are still planning to invest in Ambrx Biopharma American check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ambrx Biopharma's history and understand the potential risks before investing.
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Transaction History View history of all your transactions and understand their impact on performance | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |